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Abstract 
Protein measurements in blood are often used to investigate the pathological contribution of individual 
molecules. Neuregulin1 (NRG1) proteins influences the development of white matter connectivity and is 
implicated in genetic susceptibility in schizophrenia (NRG1  proteins in rat, Frenzel, NRG1 1 genetic variation 
Fei Wang). Neuregulin 1 affects the regulation of central nervous system myelination by inducing the migration 
and differentiation of oligodendrocytes in the CNS. The objective of the present study is to make comparison of 
immunoreactivity serum Neuregulin 1 in Bataks ethnic with schizophrenia and Bataks ethnic healthy control. 
Serum samples were collected from 42 Bataks ethnic with schizophrenia (21 men, 21 women) and 30 control 
subjects (15 men, 15 women). Neuregulin 1 was measured by ELISA using antibody against NRG 1 beta 1. The 
differences between Bataks ethnic with schizophrenia and healthy control were assessed using Mann Whitney 
test (significant value p < 0,05). Mean immunoreactivity of serum Neuregulin 1 in schizophrenic patients 14,51 
pg/ml (SD ± 6,81) and mean immunoreactivity of serum neuregulin 1 in control subjects 13,12 pg/ml (SD ± 
2,49). Immunoreactivity of serum neuregulin 1 in Batak ethnics with schizophrenia was significantly higher than 
in Bataks ethnic healthy control (p=0,036).  
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1. Introduction 
Schizophrenia is a complex genetic disorder that carries lifetime morbid risk of 1% across different populations 
with different cultures (Stefansson et al., 2002; Williams et al., 2003; Li, Collier dan He, 2006; Mc Grath et al., 
2009; Nieratschker, Nothen dan Rietscel, 2010). Schizophrenia paranoid is one of the most common type of 
schizophrenia which is characterized by preoccupation with one or more delusion or frequent auditory 
hallucination (Sadock dan Sadock, 2007; Goldberg, David dan Gold, 2011; Yeganeh et al., 2011). Neuregulin1 
(NRG1) proteins are implicated in the differentiation and myelination of Schwann cells and oligodendrocytes, 
the migration of CNS neuronal precursors along radial glia, synaptogenesis, plasticity and regulation of 
neurotransmitter receptors (Kircher et al., 2009). NRG1 seems to play a major role in neurodevelopment, both 
during fetal gestation and postnatal reorganization and myelination processes, which continue until early 
adulthood. Evidence shows that NRG1 signalling is altered in schizophrenia (Stahl, 2008; Hall et al., 2006; 
Dammann et al., 2008; Kircher et al., 2009; Buonanno, 2010; Haraldsson et al., 2010). 
 
2. Subjects and Methods 
This study was approved by the Research Ethics Committee of Medical Faculty University of Sumatera Utara. 
Forty–two Bataks ethnic patients with schizophrenia paranoid from Pempropsu mental hospital and thirty Bataks 
ethnic as healthy control were recruited as participants. All subjects were Batak ethnic with schizophrenia 
paranoid, cooperative, age between 15 and 55 years old. Exclusion criteria for all subjects were having severe 
medical illness: especially heart disease, having other psychiatric disorder and pregnant. Written informed 
consent was obtained from all participants after giving a full explanation of the study protocol. Semi-structured 
interviews using MINI-ICD X were carried out for all participants. Diagnoses of schizophrenia paranoid were 
made based on ICD X criteria. Control subjects were recruited primarily from the staff of participating hospitals 
and associated laboratories. We matched the ages and genders of the control healthy volunteers to those of the 
patients examined. Serum samples were collected from 42 Bataks ethnic with schizophrenia paranoid and 30 
healthy control subjects. 
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2.1. Blood sampling 
Blood was collected in tubes between 9 and 12 a.m. Within 1 hour of collection, blood was coagulated at 370C 
for 60 min. Serum was separated by centrifugation at 40C for 15 min and stored at -800C until use for analysis. 
2.2. NRG enzyme immunoassay  
We have established an enzyme-linked immunosorbent assay (ELISA), using Ab100614  human NRG1 beta 1 
(Neuregulin 1 beta 1) ELISA (Enzyme-Linked Immunosorbent Assay). Ab100614 Human NRG1 beta 1 
(Neuregulin 1 beta 1) ELISA (Enzyme-Linked Immunosorbent Assay) kit is an in vitro enzyme-linked 
immunosorbent assay for the quantitative measurement of human NRG1 beta 1 in serum, plasma (collect plasma 
using EDTA or citrate as an anticoagulant. Heparinized plasma are not recommended), cell culture supernatants 
and urine. This assay employs an antibody specific for human NRG1 beta 1 coated on a 96-well plate. Standards 
and samples are pipetted into the wells and NRG1 beta 1 present in a sample is bound to the wells by the 
immobilized antibody. The wells are washed and biotinylated anti-human NRG1 beta 1 antibody is added. After 
washing away unbound biotinylated antibody, HRP-conjugated streptavidin is pipetted to the wells. The wells 
are again washed, a TMB substrate solution is added to the wells and color develops in proportion to the amount 
of NRG1 beta 1 bound.  
2.3. Statistical Analysis 
Univariat analysis was performed to describe each variable and was described by frequency table. The putative 
confounding factors included age and gender were analyzed between the Batak ethnics with schizophrenia and 
without schizophrenia by using X2 test. 
Bivariat analysis was performed to analyze whether there are differences between immunoreactivity NRG1 
serum in Batak ethnics with schizophrenia and healthy control. The immunoreactivity NRG1 serum data was 
analyzed by using t-independent test if the data was normally distributed, or Mann-Whitney test if it was not 
normally distributed. Statistical analysis was performed using SPSS software (version 15.0). The probability 
level of p<0,05 and confidence interval 95% was considered to be statistically significant.  
 
3. Result 
Serum of Bataks ethnic with schizophrenia paranoid (n = 42) and Bataks ethnic healthy control (n = 30) were 
obtained. We matched age and gender of healthy control to those of the patients examined. Minimizing the 
influence of differences in sampling conditions, we did consistent procedures which involved the time of blood 
collecting and coagulation procedure. 
NRG1 immunoreactivity serum of Bataks ethnic schizophrenia paranoid patients (mean 14,51 ± 6,81 pg/ml) was 
significantly higher than those in Bataks ethnic healthy control (mean 13,12 + 2,49 pg/ml, p = 0,036). There was 
no statistically difference between NRG1 immunoreactivity serum in Bataks ethnic schizophrenia paranoid men 
(mean 15,29 + 9,52 pg/ml) than in Bataks ethnic healthy control men (mean 14,02 + 3,07 pg/ml, p = 0,574). 
NRG1 immunoreactivity serum in Bataks ethnic schizophrenia paranoid women (mean 13,72 + 1,72 pg/ml) was 
significantly higher than in Bataks ethnic healthy control women  (mean 12,22 + 1,30, p=0,012). 
To estimate the correlations among levels of immunoreactivity NRG 1, age, onset, duration of illness and dose of 
antipsychotic medication, we performed Spearman correlation analysis. There were no correlation among age 
(R=0,09, p=0,46), age at onset (R=0,15, p=0,34), duration of illness (R=0,14, p=0,36), dose of antipsychotic 
medication (R=-0,16, p=0,31 ) and levels of immunoreactivity neuregulin 1. 
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Tabel 1. Characteristic of Study Participants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tabel 2. Comparison of NRG1 Immunoreactivity Serum of Bataks Ethnic Schizophrenia Paranoid 
Patients and  Bataks Ethnic Healthy Control 
 
 
 
 
 
4. Discussion 
We established ELISA for NRG1 and measured NRG1 immunoreactivity in serum to evaluate the pathological 
influences of schizophrenia on NRG1 protein. We found that NRG1 immunoreactivity Bataks ethnic 
schizophrenia paranoid patients were significantly higher than those in healthy control. NRG1 expression is 
induced by adult ischemic and traumatic brain injury, as well as by neonatal hypoxia. Thus, it is possible that the 
more abnormal expression of NRG1 is induced in human embryos or neonates carrying these SNPs by these 
environmental insults, the more severely this factor might impair brain development to increase the risk of 
schizophrenia. The latter report is consistent with our present findings on NRG1expression in serum. Shibuya et 
al (2010) found that immunoreactivity NRG1 healthy control serum were significantly higher than those in 
patients. There were several studies examining the expression of NRG1 mRNA in postmortem brains of patients 
with schizophrenia, most have reported an increase in mRNA levels. The hippocampus and prefrontal cortex of 
schizophrenia patients contain higher levels of type-I mRNA than samples from control subjects (Hashimoto et 
al., 2004; Law et al., 2006; Petryshen et al., 2005) report an increase in mRNA encoding type-III NRG1 
precursor (SMDF), while Zhang et al. (2008) detect decreases in type-I and type-II mRNAs encoding NRG1 
precursors (HRG-b3 and GGF2) in patient lymphocytes. 
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Figure 1. Immunoreactivity NRG1 Serum Curve. The concentration variation from 9,474 pg/mL to 
56,279 pg/mL 
We found there were no significantly correlations among age, age at onset, duration of illness, dose of 
antipsychotic medication and level of immunoreactivity NRG1 serum. There was slight correlation between age 
and level of immunoreactivity NRG1 serum. It might because of matching that have done. There were slight 
correlation among age at onset, duration of illness and level of immunoreactivity NRG1 serum. Hahn suggested 
that chronic haloperidol treatment significantly reduces NRG1-mediated ErbB4 activation in mice (Hahn et al., 
2006). It is possible that the protein expression levels of NRG1 and ErbB receptors are also modified by chronic 
antipsychotic drug treatment, and these alterations might contribute to the pharmacological action of 
antipsychotic drugs. 
 
5. Strength and Limitation 
It was the first study to investigate immunoreactivity NRG1 serum in Bataks Ethnic and in Indonesia. We also 
had controlled confounding factors such as age, gender and psychosocial stressor which in previous study these 
factors had association in immunoreactivity NRG1. 
In this study, duration of medication and severity of illness were not evaluated. Theoretically, the course of 
schizophrenia is influenced by those factors. Furthermore, it could modulate the pharmacotherapy, at the end it 
was possible to influence expression of the protein. 
We hope that the ELISA system for NRG1 peptide will help to explore its biological role in schizophrenia 
pathogenesis or screening tools for schizophrenia. 
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